WÖRWAG R&D GmbH - Company profile for products to licenceoutWörwag Research and Development GmbHA subsidiary of the Wörwag...
WÖRWAG R&D GmbH - Company profile for products to licenceoutWörwag Research and Development GmbHBusiness model  ● Licensin...
WÖRWAG R&D GmbH - Company profile for products to licence out(I)Readily Compiled Dossiers (I):Following dossiers are readi...
WÖRWAG R&D GmbH - Company profile for products to licence out(II)Readily Compiled Dossiers (II):     ● Valsartan tablets (...
WÖRWAG R&D GmbH - Company profile for products to licence out(III)Readily Compiled Dossiers (III):     ● Torasemid tablets...
WÖRWAG R&D GmbH - Company profile for products to licence out(IV)Ongoing developments  ● Candesartan-HCT tablets (8/12,5 |...
WÖRWAG R&D GmbH - Company profile for products to licenceout  Contact  Wörwag R & D GmbH  Calwer Str. 7  D-71034 Böblingen...
Upcoming SlideShare
Loading in...5
×

Woerwag RD presentation

441

Published on

Published in: Business, News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
441
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Woerwag RD presentation

  1. 1. WÖRWAG R&D GmbH - Company profile for products to licenceoutWörwag Research and Development GmbHA subsidiary of the Wörwag Pharma Group dedicated to the development of: ● Generic ● OTC ● NCE products and ● Medical devicesaccording to European guidelinesMission ● Provide excellent products right in time for launch with maximum therapeutic benefit for our patientsMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
  2. 2. WÖRWAG R&D GmbH - Company profile for products to licenceoutWörwag Research and Development GmbHBusiness model ● Licensing-out developments done by Wörwag R&D in Europe and Worldwide on a national, European or worldwide basis.Please find Wörwag R&D’s current development list and compiled / approveddossiers on the following pages or on our homepage:www.woerwag-rd.comMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
  3. 3. WÖRWAG R&D GmbH - Company profile for products to licence out(I)Readily Compiled Dossiers (I):Following dossiers are readily compiled and have received German and selectedEuropean Marketing Authorisations. They are ready for submission in othermarkets: ● Clopidogrel film coated tablets (75 mg); Original: Plavix, Iscover ● Candesartan tablets (2 | 4 | 8 | 16 | 32 mg), Original: Atacand ● Donepezil film coated tablets (5 | 10 mg), Original: Aricept ● Levetiracetam film coated tablets (250 | 500 | 750 | 1000 mg), Original: Keppra ● Pioglitazon tablets (15 | 30 | 45 mg), Original: Actos of German origin (Bulk and Packaging)March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
  4. 4. WÖRWAG R&D GmbH - Company profile for products to licence out(II)Readily Compiled Dossiers (II): ● Valsartan tablets (40 | 80 | 160 | 320 mg), Original: Diovan of German origin (Bulk and Packaging) ● Losartan film coated tablets (12,5 | 25 | 50 | 100 mg); Original: Lorzaar ● Losartan-HCT film coated tablets (50/12,5 | 100/12,5 | 100/25 mg); Original: Lorzaar PlusMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
  5. 5. WÖRWAG R&D GmbH - Company profile for products to licence out(III)Readily Compiled Dossiers (III): ● Torasemid tablets (2,5 | 5 | 10 | 20 | 200 mg); Original: Torem, Unat ● Xipamid tablets (10 | 20 | 40 mg); Original: Aquaphor ● Enalapril-HCT tablets (20/12,5 mg); Original: Benalapril Plus ● HCT tablets (12,5 | 25 mg); Original: Esidrix ● Milk Thistle Dry Extract, film coated tablets, corresponding to 150 mg Silymarin (UV) ● Milk Thistle Dry Extract, capsules, corresponding to 86,5 mg Silymarin (HPLC) ● Capsicum Cream (0,05 % Capsaicin), OTC product indicated for pain relief due to chronic diabetic neuropathy All products above are of German origin (Bulk and Packaging)March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
  6. 6. WÖRWAG R&D GmbH - Company profile for products to licence out(IV)Ongoing developments ● Candesartan-HCT tablets (8/12,5 | 16/12,5 | 32/12,5 | 32/25 mg), Dossier ready until Q III-2011, DCP in Q IV-2011; Original: Atacand Plus ● Galantamine XR capsules (8 | 16 | 24 mg), Dossier ready,DCP ongoing; Original: Reminyl ● Duloxetin gastro-resistant capsules (30 | 60 mg),Dossier ready in 2012, Data protection period until Aug. 2014; Original: Cymbalta of German origin (Bulk and Packaging)Please find more details on our homepage at:www.woerwag-rd.comMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
  7. 7. WÖRWAG R&D GmbH - Company profile for products to licenceout Contact Wörwag R & D GmbH Calwer Str. 7 D-71034 Böblingen Germany Dr. Wolfgang Bäurle Head Business Development Tel.: +49 7031-6204-794 Fax: +49 7031-6204-72 E-mail: Wolfgang.Baeurle@woerwagpharma.com Internet: www.woerwag-rd.comMarch 2011 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×